1
|
Venegas-Rodríguez R, Serrano-Díaz A, Peña-Ruiz R, Santana-Sánchez R, Hernández-Cedeño M, Rittoles Navarro A, Grecesqui-Cruz I, Pérez-Aguilera L, Segura-Fernández A, Rosario-Cruz L, Martínez-Donato G, Guillén-Nieto G, Domínguez- Horta MDC. Jusvinza, an anti-inflammatory drug derived from the human heat-shock protein 60, for critically ill COVID-19 patients. An observational study. PLoS One 2023; 18:e0281111. [PMID: 36730325 PMCID: PMC9894446 DOI: 10.1371/journal.pone.0281111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Accepted: 12/06/2022] [Indexed: 02/03/2023] Open
Abstract
This paper presents the results of an observational and retrospective study on the therapeutic effects of Jusvinza, an immunomodulatory peptide with anti-inflammatory properties for critically ill COVID-19 patients. This peptide induces regulatory mechanisms on the immune response in experimental systems and in patients with Rheumatoid Arthritis. Exploratory research in COVID-19 patients revealed that Jusvinza promotes clinical and radiological improvement. The aim of this study is to describe the clinical outcome and variations of several inflammatory biomarkers in a cohort of critically ill COVID-19 patients, divided into two groups during the observational research: one group received Jusvinza and the other did not. Research physicians extracted the patients´ data from their hospital's clinical records. The study analyzed 345 medical records, and 249 records from critically ill patients were included. The data covered the demographic characteristics, vital signs, ventilatory parameters and inflammatory biomarkers. Survival outcome was significantly higher in the group receiving Jusvinza (90.4%) compared to the group without Jusvinza (39.5%). Furthermore, in patients treated with Jusvinza there was a significant improvement in ventilatory parameters and a reduction in inflammation and coagulation biomarkers. Our findings show that Jusvinza could control the extent of inflammation in COVID-19 patients. This study indicates that Jusvinza is a helpful drug for the treatment of diseases characterized by hyperinflammation.
Collapse
Affiliation(s)
| | - Anabel Serrano-Díaz
- Biomedical Research Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | | | | | - Mabel Hernández-Cedeño
- Biomedical Research Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | | | | | | | | | | | - Gilliam Martínez-Donato
- Biomedical Research Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - Gerardo Guillén-Nieto
- Biomedical Research Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | | |
Collapse
|
2
|
Hernandez-Cedeño M, Venegas-Rodriguez R, Peña-Ruiz R, Bequet-Romero M, Santana-Sanchez R, Penton-Arias E, Martinez-Donato G, Guillén-Nieto G, Dominguez-Horta MDC. CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients. Cell Stress Chaperones 2021; 26:515-525. [PMID: 33629254 PMCID: PMC7904296 DOI: 10.1007/s12192-021-01197-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2020] [Revised: 02/05/2021] [Accepted: 02/08/2021] [Indexed: 12/15/2022] Open
Abstract
Hyperinflammation distinguishes COVID-19 patients who develop a slight disease or none, from those progressing to severe and critical conditions. CIGB-258 is a therapeutic option for the latter group of patients. This drug is an altered peptide ligand (APL) derived from the cellular stress protein 60 (HSP60). In preclinical models, this peptide developed anti-inflammatory effects and increased regulatory T cell (Treg) activity. Results from a phase I clinical trial with rheumatoid arthritis (RA) patients indicated that CIGB-258 was safe and reduced inflammation. The aim of this study was to examine specific biomarkers associated with hyperinflammation, some cytokines linked to the cytokine storm granzyme B and perforin in a cohort of COVID-19 patients treated with this peptide. All critically ill patients were under invasive mechanical ventilation and received the intravenous administration of 1 or 2 mg of CIGB-258 every 12 h. Seriously ill patients were treated with oxygen therapy receiving 1 mg of CIGB-258 every 12 h and all patients recovered from their severe condition. Biomarker levels associated with hyperinflammation, such as interleukin (IL)-6, IL-10, tumor necrosis factor (TNF-α), granzyme B, and perforin, significantly decreased during treatment. Furthermore, we studied the ability of CIGB-258 to induce Tregs in COVID-19 patients and found that Tregs were induced in all patients studied. Altogether, these results support the therapeutic potential of CIGB-258 for diseases associated with hyperinflammation. Clinical trial registry: RPCEC00000313.
Collapse
Affiliation(s)
- M Hernandez-Cedeño
- Biomedical Research Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, 11300, Havana, Cuba
| | - R Venegas-Rodriguez
- Luis Díaz Soto Hospital, Avenida Monumental km 2, Habana del Este, Havana, Cuba
| | - R Peña-Ruiz
- Luis Díaz Soto Hospital, Avenida Monumental km 2, Habana del Este, Havana, Cuba
| | - M Bequet-Romero
- Biomedical Research Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, 11300, Havana, Cuba
| | - R Santana-Sanchez
- Luis Díaz Soto Hospital, Avenida Monumental km 2, Habana del Este, Havana, Cuba
| | - E Penton-Arias
- Biomedical Research Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, 11300, Havana, Cuba
| | - G Martinez-Donato
- Biomedical Research Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, 11300, Havana, Cuba
| | - G Guillén-Nieto
- Biomedical Research Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, 11300, Havana, Cuba
| | | |
Collapse
|